839 members551 posts


Effect of dehydroepiandrosterone supplementation on fatty acid and hormone levels in patients with X-linked adrenoleucodystrophy.


Dehydroepiandrosterone supplementation for 3 months did not lower the elevated plasma levels of saturated very long-chain fatty acids in patients with X-linked adrenoleucodystrophy. Instead, a decrease in saturated and mono- and polyunsaturated fatty acids in erythrocytes and plasma was found. An increase of C20:1omega-9 was found in plasma only.

That's from 2003.

Dehydroepiandrosterone up-regulates the Adrenoleukodystrophy-related gene (ABCD2) independently of PPARalpha in rodents.

Here, we explored the in vitro and in vivo effects of DHEA on the expression of peroxisomal ABC transporters. We show that Abcd2 and Abcd3 but not Abcd4 are induced in primary culture of rat hepatocytes by DHEA-S. We also demonstrate that Abcd2 and Abcd3 but not Abcd4 are inducible by an 11-day treatment with DHEA in the liver of male rodents but not in brain, testes and adrenals. Finally and contrary to Abcd3, we show that the mechanism of induction of Abcd2 is independent of PPARalpha.

That's from 2007.

Regardless, I've got some DHEA. I'll give it a go. I like how they say it upregulates ABCD2.

Stay well, comrades.

3 Replies

And more

This next one is from 2002.


I cherry picked this bit....

A drug should be selected that upregulates specific

components belonging to the metabolic function that is

impaired. In this respect, our results suggest that DHEA

is a candidate drug for the treatment of X-ALD

Of course, I am just picking the bits I want to hear.

Have a read of the conclusion of this one.


Hey monkeybus are you on facebook. I have a page on there called

ALD/AMN FAMILY you're welcome to join. I think I posted on here before about it.


Thanks a lot deengo, I'll take a look.


You may also like...